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Abstract
Background: Telomeres are the protective arrays of tandem TTAGGG sequence and associated proteins at the
termini of chromosomes. Telomeres shorten at each cell division due to the end-replication problem and are
maintained above a critical threshold in malignant cancer cells to prevent cellular senescence or apoptosis. With
the recent advances in massive parallel sequencing, assessing telomere content in the context of other cancer
genomic aberrations becomes an attractive possibility. We present the first comprehensive analysis of telomeric
DNA content change in tumors using whole-genome sequencing data from 235 pediatric cancers.
Results: To measure telomeric DNA content, we counted telomeric reads containing TTAGGGx4 or CCCTAAx4 and
normalized to the average genomic coverage. Changes in telomeric DNA content in tumor genomes were
clustered using a Bayesian Information Criterion to determine loss, no change, or gain. Using this approach, we
found that the pattern of telomeric DNA alteration varies dramatically across the landscape of pediatric
malignancies: telomere gain was found in 32% of solid tumors, 4% of brain tumors and 0% of hematopoietic
malignancies. The results were validated by three independent experimental approaches and reveal significant
association of telomere gain with the frequency of somatic sequence mutations and structural variations.
Conclusions: Telomere DNA content measurement using whole-genome sequencing data is a reliable approach
that can generate useful insights into the landscape of the cancer genome. Measuring the change in telomeric
DNA during malignant progression is likely to be a useful metric when considering telomeres in the context of the
whole genome.
Background
Telomeres are the protective caps at the ends of chro-
mosomes and are composed of telomeric DNA repeats,
TTAGGG, and associated proteins. The telomeres are
critical for genomic stability, as they prevent chromo-
some ends from being recognized as double strand
breaks; they prevent end-to-end chromosome fusions
and help maintain replicative competence. Telomere
length varies widely among individuals at birth [1] and
decreases with each cell division since the DNA replica-
tion machinery is unable to replicate chromosome ends
(’end-replication problem’). Telomere attrition inevitably
reaches a critical point at which cellular senescence or
apoptosis is triggered [2]. Approximately 85% of cancers
[3] escape the cellular crisis caused by telomere shorten-
ing by activating telomerase, an enzyme that catalyzes
the synthesis of telomeric DNA from an RNA template.
An alternative mechanism to lengthen telomeres has
also been observed in a small number of malignancies
termed ‘alternative lengthening of telomeres’ (ALT) [4].
This mechanism operates in a telomerase-independent
fashion and is characterized by the production of long,
heterogeneous telomeres [5] that can be identified as
large bright nuclear foci by fluorescence in situ hybridi-
zation (FISH) [6].
A number of experimental methods have been used to
measure telomere length. Telomere restriction fragment
(TRF) analysis involves digesting a large quantity of
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genomic DNA (1.5 to 2 µg) with enzymes that cut near
the ends of the chromosomes. Southern blotting of this
DNA with a telomere probe detects the sizes of the
restriction fragments generated and thereby provides an
average telomere length estimation. FISH can be useful
for detecting ALT, but without a metaphase spread it is
difficult to judge total telomeric DNA content. A high-
throughput technique favored by those carrying out
large studies is quantitative PCR (qPCR) with two reac-
tions - one with primers specific for telomeric sequence
and one with a single copy gene to allow normalization
[7,8].
The development of massively parallel sequencing,
that is, next-generation sequencing, provides an alterna-
tive and potentially highly robust method to measure
telomeres. Castle et al. [9] previously suggested a poten-
tial application for whole-genome sequencing (WGS) to
ascertain telomeric DNA content. By counting and nor-
malizing WGS reads containing the telomere repeats
(TTAGGG)4, they reported that a lung carcinoid cell
line had fewer telomere reads compared with the pooled
DNA of healthy individuals [9]. This in silico finding,
although consistent with the hypothesis that cell lines
may have shorter telomeres due to many cycles of cell
divisions, has several caveats. First, the observation was
based on a single cell line with no experimental valida-
tion. Second, since the normal control DNA employed
was not matched to the cell line source, it remains
unclear if normal heterogeneity in telomere length
might have contributed to the observed telomere differ-
ence. At present, the potential application of using WGS
for telomere analysis has not been explored.
In this study we present the first comprehensive char-
acterization of telomeres in primary tumors using WGS
data from The St Jude Children’s Research Hospital -
Washington University Pediatric Cancer Genome Pro-
ject (PCGP). The PCGP is sequencing 600 pediatric can-
cers and their matched normal DNA to identify somatic
lesions that drive the initiation, biological and clinical
behavior of pediatric cancers. It was launched in 2010
and WGS is complete for over 235 tumors from 15 dif-
ferent types of pediatric cancers with an average of 30-
fold haploid coverage [10], making it possible to carry
out a comprehensive telomere analysis using WGS data
[11-14].
Results and discussion
WGS telomeric DNA content and age
To evaluate the reliability of using WGS data for charac-
terizing telomeric DNA content, we first compared the
normalized count of reads containing telomere repeat
(TTAGGG)4 of matched normal DNA from PCGP
patients with that of normal DNA of 13 adult cancer
patients from The Cancer Genome Atlas (TCGA). All
samples used for this analysis were from either periph-
eral blood or bone marrow [15,16]. A reduction in telo-
mere repeats with age is expected as telomeres erode at
each normal somatic cell division. This result shows
that the number of telomeric reads in adult sample was
significantly lower than observed in three pediatric can-
cer groups (P = 0.02 by Mann-Whitney test; Figure 1),
demonstrating that WGS is able to detect age-depen-
dent changes in telomere length.
WGS telomeric DNA content in matched tumor normal
pairs
The original method by Castle et al. counted the num-
ber of reads containing (TTAGGG)4 and normalized to
the average genomic coverage. We modified this
approach by first normalizing the number of reads con-
taining the telomeric sequence (TTAGGG)4 or its
reverse complementary sequence (CCCTAA)4 relative to
WGS average coverage, and then calculating the change
in telomeric DNA content in tumor samples (ΔT) as the
log2 ratio of the number of telomere reads in a tumor
sample relative to a matched non-tumor sample from
the same patient. This approach minimizes the effect of
WGS coverage, a patient’s age, and inter-individual telo-
mere-length heterogeneity on the determination of telo-
meric DNA changes in tumor cells. To classify this
change, we used Bayesian information criterion (BIC)-
guided clustering of ΔT for all tumors to determine
whether there was a gain, loss or no change in tumor
telomere compared to normal DNA (Figure 2a).
We applied this method to 235 PCGP pediatric cancer
genomes (Figure 2d) comprising 13 different cancer
types. We found significant gains of telomeric DNA in
32% of solid tumors. In contrast, hematopoietic malig-
nancies show near uniform loss of telomeric DNA and
only 4% of brain tumors have telomere gain. Specifically,
all of the core binding factor (CBF) acute myeloid leuke-
mia (AML) tumors were found to have loss of telomeric
DNA, 79% of hypo-diploid (HYPO) acute lymphoblastic
leukemia (ALL), 77% of infant (INF) ALL, and 92% of
early T-cell precursor ALL (ETP ALL ) had loss, while
the remaining tumors of the hematopoietic malignancies
group had no change in telomeric DNA. In brain tumor
the majority (72%) of ependymoma (EPD) samples had
no change in telomeric DNA while the remainder had
loss. A similar pattern was observed in low-grade glio-
mas (LGG) as 80% of tumors had no change and 20%
had loss. By contrast 85% of medulloblastoma had loss
of telomeric DNA but one outlier (SJMB004, discussed
below) had marked gains in telomeric DNA. High-grade
gliomas had gains in 27%, losses in 36% and no change
in 36% of tumors. The following members of the solid
tumor malignancies had more gains in telomeric DNA:
adrenocortical carcinoma (ACT, 50%), neuroblastoma
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Figure 1 Association with matched non-tumor telomeric DNA content and age. (a) Comparison of age distribution of pediatric PCGP
samples and adult TCGA samples. Because of the narrow range of age distribution in pediatric cancer in PCGP (n = 235, median = 7.5) we
included 13 samples from TCGA (n = 13, median = 56) to enable evaluation of association between telomere length with age. (b) Comparison
of distribution of normalized telomere count in matched normal DNA of pediatric patients with that of the adult patients. The reduction of
telomere reads in adult is statistically significant (Wilcoxon signed rank P = 0.00046).
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Figure 2 Telomere analysis using whole-genome sequencing data of 235 pediatric cancers. (a) Bayesian information criterion (BIC) guided
clustering, which divided the ΔT values in this cohort into two clusters with equal variance. The boundary of these clusters is marked in dark
blue. Using 0.01 as the threshold for significance, we defined the lower and upper boundary of ΔT as ‘gain’ or ‘loss’ of telomeric DNA. Samples
that fall within these boundaries are deemed to have ‘no change’ in telomere status. (b) The number of structural variations in tumors with
‘gain’, ‘loss’ or ‘no change’ of telomere status. Tumors with ΔT gains have significantly higher number of structural variations compared with the
other two groups (Mann-Whitney P = 1.07e-10; brain tumors P = 0.013, solid tumors P = 0.0002, hematopoietic malignancies P = NA (Not
Applicable - no telomeric content gains detected); M, median). (c) The number of non-silent mutations in tumors with ‘gain’, ‘loss’ or ‘no change’
of telomere status. Tumors with ΔT gains have significantly higher number of sequence mutations compared with the other two groups (Mann-
Whitney P = 3.723e-07; brain tumors P = 0.061; solid tumors P = 0.013, hematopoietic malignancies P = NA; M, median). (d) ΔT values from 235
pediatric cancers. The dotted lines correspond to the lower and upper boundary of ΔT as ‘gain’ or ‘loss’. CBF, core-binding factor ALL; HYPO,
hypodiploid ALL; INF, infant ALL; TALL, ETP-ALL; EPD, ependymoma; HGG, high-grade glioma; LGG, low-grade glioma; MB, medulloblastoma, ACT,
adrenocortical carcinoma; NBL, neuroblastoma; OS, osteosarcoma; RB, retinoblastoma; RHB, rhabdomyosarcoma.
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(NBL, 27%) and osteosarcoma (OS, 61%). However, the
dominant pattern in rhabdomyosarcoma (RHB) and reti-
noblastoma (RB) was loss of telomeric DNA, 62% and
75%, respectively. Telomeric DNA content for several
pediatric tumors were previously studied and our results
support previously published findings (comprehensively
reviewed in [17]), that is, leukemia had shorter telo-
meres with no evidence for ALT [18,19], some of the
ACT had very long telomeres indicative of ALT [19,20],
a high proportion of osteosarcoma had long heteroge-
neous telomeres with ALT [21-23], NBLs had highly
variable telomere lengths [24], and some of the high-
grade gliomas had ALT and long telomeres [25]. This
concordance provides a strong indication that telomeric
DNA content measurement by WGS is applicable to
multiple tumor types.
To evaluate the variability of telomere content estima-
tions from WGS, we determined the telomeric DNA
content for two infant ALL tumors that occurred in a
pair of twins. Both tumors share the same initiating
translocation of myeloid/lymphoid or mixed-lineage leu-
kemia (MLL) gene, confirming that the twin pairs of
leukemia have a common clonal origin, as expected
from previous research on twins with concordant leu-
kaemia [26]. Therefore, the twin pair of tumors can be
considered a biological replica given their common clo-
nal origin. The normalized read count for each tumor in
the twin pair was very similar (2,266 versus 2,545),
showing high reproducibility of telomere analysis by our
approach (Figure S1 in Additional file 1).
We examined telomere changes in the context of
other somatically acquired genomic aberrations. Inter-
estingly, tumors with telomere gains also contained a
significantly higher frequency of genomic structural var-
iations, which include deletions, inversions, insertions,
intra- and inter-chromosomal rearrangements (Figure
2b; Mann-Whitney P = 1.07 × 10-7). Additionally, they
had significantly higher numbers of non-silent somatic
sequence mutations (Figure 2c; Mann-Whitney P =
3.723 × 10-7) compared with those with no change or
loss of telomeres. When considering only brain tumors
or solid tumors (no telomere gain in hematopoietic
malignancies), telomere gain was significantly associated
with structural variations (P-values for brain and solid
tumor are 0.013 and 0.0002, respectively) but the asso-
ciation with sequence mutations was observed only in
solid tumors (P = 0.013; brain tumors P = 0.061). In
contrast to non-tumor DNA, no significant relationship
was observed between patient age and telomere gain or
loss status in tumors (Figure 3).
Validation of telomeric DNA content predictions
To validate our method of measuring telomere length
from WGS data, we used three independent assays of
telomere length. First, quantitative PCR [27] was used to
validate telomere change identified by analysis of WGS
data in 25 tumors using DNA from both tumor and
matched non-tumor samples. We used ΔTqPCR , that is,
the log2 ratio of total absolute telomere quantity in
tumor compared to non-tumor based on qPCR and
found 88% of the tumors show consistent telomere sta-
tus between WGS and qPCR (Figure 4a; Table S1 in
Additional file 2). Second, 30 samples were subjected to
interphase FISH analysis. Using this method, it was pos-
sible to determine only ‘normal’ or ‘abnormal’ telomeres.
Therefore, telomere gain by WGS analysis is considered
‘abnormal’ while the remaining cases are considered
‘normal’; 87% of the telomere status predictions by
WGS were concordant with telomere FISH (Table S1 in
Additional file 2). SJMB004, a medulloblastoma with a
marked gain of telomeric DNA by WGS, had large
ultra-bright telomere foci expected from cells utilizing
ALT (Figure 4b). In contrast, ALT was absent in
SJMB028, a sample predicted to be ‘normal’ by WGS.
The third validation experiment was TRF analysis by
southern blotting on two samples with sufficient quan-
tity of genomic DNA, SJOS002 and SJOS004 (Figure
4c). SJOS002 and SJOS004 were predicted to have gain
and loss of telomeric DNA by WGS (Figure 4d) and
qPCR (Figure 4e), respectively, and TRF analysis sup-
ports these findings.
Conclusions
Our study is the first application of WGS to measure
telomeric DNA content in a large collection of primary
tumors. Our extensive validation shows that WGS ana-
lysis is a reliable approach for determining telomeric
DNA content changes in cancer genomes. It should be
noted, however, that telomeric DNA content assessment
by WGS has comparable pitfalls to those of qPCR, that
is, chromosome by chromosome telomere length cannot
be quantified and contribution of telomeric repeats in
non-telomeric regions of the genome cannot be deter-
mined. Our findings not only corroborate previous
reports of telomeric DNA content in several pediatric
cancers [17], they also add a significant amount of telo-
mere status information to tumors that have not been
adequately studied. Furthermore, integrating tumor telo-
meric state (’gain’, ‘loss’, or ‘no change’) with other
somatic lesions such as sequence mutations and struc-
tural variations in one single WGS experiment provides
additional insight into the landscape of genetic altera-
tions in cancer. For example, significant association
between telomere change and structural variation sug-
gests that telomere gain could be a hallmark of genome
instability. Integrating sequence mutations with the telo-
mere features may identify causal mutations for the
abnormal telomere phenotypes. For example, we have
Parker et al. Genome Biology 2012, 13:R113
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previously reported that mutations in ATRX are linked
to telomeric gains in NBL [12]: of the ten NBL tumors
with ATRX somatic alterations, eight have longer telo-
meres. Although our analysis was based on WGS, we
anticipate that similar approaches can be applied for
transcriptome sequencing (RNA-seq) data by analyzing
aberrantly expressed telomeric DNA.
Materials and methods
Patients and samples
The use of human tissues for WGS was approved by the
institutional review boards of St Jude Children’s
Research Hospital, Memorial Sloan-Kettering Cancer
Center, and Washington University in St Louis (St Jude
IRB# FWA00004775, Protocol# XPD09-018). Written
informed consent and/or assent was obtained from
patients and/or legal guardians at the time of the surgi-
cal resection or bone marrow procedure. Matched nor-
mal samples were obtained either from peripheral blood,
bone marrow or adjacent normal tissue.
Whole genome sequencing
Illumina 100 bp paired-end sequencing was performed
for tumor and normal DNA from 235 subjectsat a high
average genomic coverage (approximately 30×). Single
nucleotide variations, insertion/deletions, were detected
by the program Bambino [28] followed by an automated
review process as described previously [11]. Structural
variations were identified by CREST [29]. The WGS
data used in this study have been deposited at the Eur-
opean Genome-phenome Archive (EGA) and data from
all of the diseases examined in this manuscript can be
found at [30]. Information on data access policies can
be found at [31]. Table 1 lists dataset IDs.
The ETP-TALL data set has just become public in EBI
under the accession EGAS00001000348. We updated
the accession in Table 1.
Assessment of telomeric DNA content using whole
genome sequencing
Reads containing the telomeric repeat (TTAGGG)4 or
(CCCTAA)4 were counted and normalized to the aver-
age genomic coverage (that is, the average number of
average reads covering each base in the reference
human genome). The normalized telomere count was
obtained separately for each tumor and its matching
normal WGS. From this the log2 ratio was calculated
giving ΔT. Adjustment for GC bias is not required
Sample Type














Figure 3 Age distribution versus telomere status. Age distribution in samples with different telomere status in tumor, that is, gain, loss and
no change. There is no significant difference in age distribution across the three groups (ANNOVA, P = 0.368).
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because at an average of 43% GC content for telomeric
reads no bias is expected for calibrating DNA abun-
dance by Illumina sequencing reads [32].
Classification of telomere change in tumors
Based on the data produced, we observed that a number
of samples had a very small ΔT (close to 0) and postu-
lated that this may reflect random variation in the telo-
mere counts produced by library preparation or
sequencing bias. Therefore, we performed Gaussian
mixture modeling on the ΔT values using the mclust
package [33] (version 3.4.8) in R-2.11.1. The optimal
model according to BIC contains two clusters, those
samples with gain and loss of telomeric DNA. Based on
this modeling we were able to classify the samples into
three groups: 1) samples that reject the null hypothesis
that the data come from the second cluster at a signifi-
cance level of 0.01. (’gain’ of telomeric DNA); 2) samples
that reject the null hypothesis that the data come from
the first cluster at a significance level of 0.01. (’loss’ of































































































































































































































Figure 4 Validation of WGS telomeric DNA content predictions. (a) Quantitative PCR for a subset of samples, including 16 medulloblastoma
and 11 neuroblastoma samples, showing changes in telomeric DNA content between normal and diagnosis log2(Absolute telomere length D/
Absolute telomere length N. (b) FISH using probes for telomeric DNA confirms the ‘normal’ and ‘abnormal’ (ultra-bright spots, white arrowheads)
telomere patterns in SJMB028 and SJMB004, respectively. (c) Telomere restriction fragment (TRF) analysis by southern blotting in 2 osteosarcoma
samples, SJOS002 and SJOS004 predicted to have telomere gain and loss by WGS, respectively. (N = matched normal DNA, D = diagnosis tumor
DNA). Inlay is the 100ng of genomic DNA on a 0.5% ethidium bromide gel which shows that the DNA quality is acceptable. (d) WGS normalized
telomeric read counts for SJOS002 and SJOS004. (e) qPCR measurement of absolute telomeric DNA in SJOS002 and SJOS004 (error bars
represent standard deviation of three technical repeats).
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FISH for telomeric DNA
Interphase FISH was performed on 4-µm-thick, forma-
lin-fixed, paraffin-embedded tissue sections. The Cy3-
labeled TelG probe (PNAbio, Thousand Oaks, CA,
USA) was co-denatured with the target cells on a hot-
plate at 90°C for 12 minutes. The slides were incubated
for 48 hours at 37°C and then washed in 4 M Urea/2×
SSC at 45°C for 5 minutes. Nuclei were counterstained
with DAPI (200 ng/ml; Vector Labs, Burlingame, CA,
USA).
Quantitative PCR measurement of absolute telomere
length
qPCR was carried out as described previously [8,12].
Diagnostic and matched normal whole genome ampli-
fied DNA (15 to 20 ng) was each subject to qPCR in
two reactions on the sample 96-well plate, one to
amplify telomeric sequence and one to amplify a com-
mon gene, RPLP0. All reactions were carried out using
Brilliant III Ultra-Fast SYBR Green master mix (Agilent)
on a Stratagene Mx3000 thermal cycler with the follow-
ing conditions; 95°C for 10 minutes followed by 40
cycles of 95°C for 15 s and 60°C for 1 minute.
Telomere restriction fragment analysis
Southern blotting was performed using the TeloTAGGG
kit (Roche Diagnostics, Indianapolis, IN, USA -
12209136001 v8.0, ). Restriction digested genomic DNA
(1.5 μg) was loaded onto a 15 cm 0.8% ultra pure agar-
ose gel and run for 2 to 4 hours at 75v. The gel was
incubated in hydrocholoric acid solution, denatured and
neutralized before transferring overnight to a positively
charged nylon membrane with 20× SSC using a What-
man (Maidstone, Kent, UK) TurboBlotter. The DNA
was fixed by exposing the membrane to UV. The mem-
brane was pre-hybridized for 60 minutes at 42°C in DIG
Easy Hyb solution before hybridization for 3 hours at
42°C with a telomere probe (10 μl probe in 10 ml pre-
warmed DIG Easy Hyb). The membrane was washed
and then blocked and incubated with anti-DIG antibody;
after another round of washing the signal was detected
using the supplied substrate solution and exposed to X-
ray film.
Calculation of validation rates
For qPCR, validation rates were calculated for those
samples that had either ‘loss’ or ‘gain’ of telomeric
DNA. Those with ‘no change’ were excluded due to the
ambiguity of their result. For FISH analysis validation
rates were calculated as follows. FISH assessment of tel-
omere normality gives two classes of sample, ‘normal’
and ‘abnormal’; no change or loss of telomeric DNA as
called by WGS would appear ‘normal’ by FISH and
those samples with gain of telomeric DNA by WGS
would be classified as ‘abnormal’ by FISH.
Statistical analysis
Statistical analysis was performed using R (version
2.11.1) and plots generated using the ggplot2 package.
Additional material
Additional file 1: Supplementary figures.
Additional file 2: Telomere calls for WGS, qPCR and FISH (where
appropriate) for all of the samples analyzed in this manuscript.
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